Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations
Zilebesiran is a first-in-class, subcutaneously administered small interfering RNA therapeutic that selectively silences angiotensinogen messenger RNA, the transcript encoding the common precursor of all angiotensin peptides and produces durable blood pressure lowering that can persist for up to 6 months after a single dose.